Feb 26, 2024 / 08:00PM GMT
Operator
Good day, everyone, and welcome to Becton, Dickinson's (BD's) Innovate Series webcast. (Operator Instructions). Please note that this call is being recorded, and an operator will be standing by should you need any assistance.
It is now my pleasure to turn today's program over to Greg Rodetis. Sir, you may begin.
Greg Rodetis - Becton, Dickinson and Company - Head of IR
Thank you, and good afternoon. I'm Greg Rodetis, Senior Vice President, Treasurer and Head of Investor Relations at BD. Welcome to the fourth episode of our BD Innovates Series, highlighting Peripheral Vascular Disease or PVD.
Before we move on, I will remind you that we'll be making forward-looking statements. I encourage you to view Slide 2 in our presentation as well as our disclosures in our SEC filings. Both are available on the IR website.
So diving into today's spotlight, PVD is 1 of our 6 key growth platforms with a category size of over $5 billion, growing high single digits. As you will hear, we are broadening our category leadership in arterial disease,
Becton Dickinson and Co To Discuss Spotlight Peripheral Vascular Disease Call Transcript
Mar 01, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers